Central Venous Thrombosis Of The Brain After Covid Infection And Vaccination

Peter McCullough is a fearless critic of conventional views about Covid and the response to it. So I read his article below with interest and attention. I was however rather confounded to see him claiming that a journal article showed the opposite of what the journal claimed.

The journal clearly claimed that the pathology they studied was vastly much less frequent among people vaccinated against Covid. McCullouch, in contrast, said that the pathology was just as likely to be found in unvaccinated people.

Looking at the raw numbers, however, I think I can follow McCulloch's reasoning. The actual numbers of people with the pathology were very small: 9 cases in the vaccinated group and 6 in the unvaccinated group. That might seem to show the vaccinated group being worse off but it overlooks the size of the populations those groups were drawn from (the denominator). As a PERCENTAGE of their respective populations, the vaccinated group was much better off.

What McCulloch does, however is to reject the denominators given. He thinks that the vaccinated group were much easier to access statistically so no comparable estimates of the denominators were possible. He just looks at the raw number of cases and says that is what matters. I think he has a point -- but the pathology is a very rare one anyway so may not be worth sustained attention

I reproduce the journal abstract below as well as McCulloch's commentary

Proponents of COVID-19 mass vaccination acknowledge that similar disastrous outcomes occur with both SARS-CoV-2 infection and the COVID-19 vaccines (myocarditis, blood clots, neurological problems)

They position a tradeoff and suggest you should risk it with the vaccine in hopes its lower than that of the infection.

Since 94 percent of Americans have had the COVID-19, its water under the bridge for the infection.

Early therapy reduces the invasive systemic manifestations of the illness and markedly reduces hospitalization and death including from complications.

With vaccination its a different story, the full force of engineered Spike protein is felt in the body with each shot and per case, the severity of the side effect is far worse than that with COVID-19.

Tu, et al illustrated this principle while analyzing central venous thrombosis which is a blood clot in the major vein of the brain which is a medical emergency requiring, hospitalization, intravenous or subcutaneous blood thinners, serial imaging, observation and in some cases surgery.

Tu attempted to divide cases by large denominators to minimize risk; that is invalid in safety research since not all cases can be found particularly fatal ones without an autopsy.

The important findings from Tu are in the tables.

Central venous thrombosis after vaccination was a catastrophe with more cases, greater need for therapy, more brain surgery, and higher degrees of neurologic impairment at discharge for those who took the mRNA vaccine.

Under no circumstances could someone accept a blood clot in the brain with the vaccine in the hopes of not getting COVID-19.

That tradeoff is untenable and yet another reason why vaccine promoters have lost trust from a discerning public.


Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore

Tian Ming Tu et al.

Key Points

Question What is the risk of cerebral venous thrombosis (CVT) after diagnosis of SARS-CoV-2 infection compared with after messenger RNA (mRNA)-based SARS-CoV-2 vaccination?

Findings In this observational cohort study of 62 447 individuals with SARS-CoV-2 infection and 3 006 662 individuals who received mRNA-based SARS-CoV-2 vaccine in Singapore from January 23, 2020, to August 3, 2021, the incidence rate ratio of CVT requiring hospitalization within 6 weeks of SARS-CoV-2 infection was 32 times higher compared with after mRNA-based SARS-CoV-2 vaccination.

Meaning These findings suggest that the risk of CVT after SARS-CoV-2 infection is higher than after mRNA-based SARS-CoV-2 vaccination.


Importance Reports of cerebral venous thrombosis (CVT) after messenger RNA (mRNA)-based SARS-CoV-2 vaccination has caused safety concerns, but CVT is also known to occur after SARS-CoV-2 infection. Comparing the relative incidence of CVT after infection vs vaccination may provide a better perspective of this complication.

Objective To compare the incidence rates and clinical characteristics of CVT following either SARS-CoV-2 infection or mRNA-based SARS-CoV-2 vaccines.

Design, Setting, and Participants Between January 23, 2020, and August 3, 2021, this observational cohort study was conducted at all public acute hospitals in Singapore, where patients hospitalized with CVT within 6 weeks of SARS-CoV-2 infection or after mRNA-based SARS-CoV-2 vaccination (BNT162b2 [Pfizer-BioNTech] or mRNA-1273 [Moderna]) were identified. Diagnosis of SARS-CoV-2 infection was based on quantitative reverse transcription-polymerase chain reaction or positive serology. National SARS-CoV-2 infection data were obtained from the National Centre for Infectious Disease, Singapore, and vaccination data were obtained from the National Immunisation Registry, Singapore.

Exposures SARS-CoV-2 infection or mRNA-based SARS-CoV-2 vaccines.

Main Outcomes and Measures Clinical characteristics, crude incidence rate (IR), and incidence rate ratio (IRR) of CVT after SARS-CoV-2 infection and after mRNA SARS-CoV-2 vaccination.

Results Among 62 447 individuals diagnosed with SARS-CoV-2 infections included in this study, 58 989 (94.5%) were male; the median (range) age was 34 (0-102) years; 6 CVT cases were identified (all were male; median [range] age was 33.5 [27-40] years). Among 3 006 662 individuals who received at least 1 dose of mRNA-based SARS-CoV-2 vaccine, 1 626 623 (54.1%) were male; the median (range) age was 50 (12-121) years; 9 CVT cases were identified (7 male individuals [77.8%]; median [range] age: 60 [46-76] years). The crude IR of CVT after SARS-CoV-2 infections was 83.3 per 100 000 person-years (95% CI, 30.6-181.2 per 100 000 person-years) and 2.59 per 100 000 person-years (95% CI, 1.19-4.92 per 100 000 person-years) after mRNA-based SARS-CoV-2 vaccination. Six (66.7%) received BNT162b2 (Pfizer-BioNTech) vaccine and 3 (33.3%) received mRNA-1273 (Moderna) vaccine. The crude IRR of CVT hospitalizations with SARS-CoV-2 infection compared with those who received mRNA SARS-CoV-2 vaccination was 32.1 (95% CI, 9.40-101; P < .001).

Conclusions and Relevance The incidence rate of CVT after SARS-CoV-2 infection was significantly higher compared with after mRNA-based SARS-CoV-2 vaccination. CVT remained rare after mRNA-based SARS-CoV-2 vaccines, reinforcing its safety.


No comments:

Post a Comment

All comments containing Chinese characters will not be published as I do not understand them